Suzhou Biomissile Biopharmaceutical Co., Ltd. is founded by leading Chinese scientists with years of experience in the biopharmaceutical industry, especially in the development and production of antibody-based drugs.

With the cutting edge discovery and optimization platform as well as multiple new macromolecule drugs under development, the pipeline currently focuses on tumor and autoimmunity, and the promotion of fully human bispecific nanobody. The main advantages of Biomissile is the early stage drug discovery with the innovative platform.